We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio
News

The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio

The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio
News

The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "The Einstein Center for Epigenomics Signs Site License Agreement with CLC bio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Einstein Center for Epigenomics at the Albert Einstein College of Medicine in Bronx, New York, has entered into an agreement with CLC bio to put the company's full suite of bioinformatics tools into the hands of epigenomics researchers and other investigators at the College.

The suite includes CLC bio’s solutions for handling high-throughput sequencing data, CLC Genomics Workbench and CLC Genomics Server.

Dr. John Greally, director of the Einstein Center for Epigenomics, is enthusiastic about the multi-year partnership, noting, "CLC bio's tools are going to put sophisticated analytical ability into the hands of molecular biologists at Einstein, and will greatly enhance their ability to explore the massively-parallel sequencing data that we are generating. We see this as a way of lowering barriers for scientists who have not previously performed these high-throughput epigenomic assays, allowing them to explore their data and explore hypotheses."

CEO at CLC bio USA, Jan Lomholdt, comments, "We’re very happy to announce this site license agreement and look forward to working with and getting valuable feedback from world-renowned scientists at Einstein. This agreement is yet another stamp of approval by the scientific community in North America, where CLC bio is currently getting a strong foothold. We will be announcing more exciting agreements in the near future."
Advertisement